Literature DB >> 27251065

Rho Kinases and Cardiac Remodeling.

Toru Shimizu1, James K Liao.   

Abstract

Hypertensive cardiac remodeling is characterized by left ventricular hypertrophy and interstitial fibrosis, which can lead to heart failure with preserved ejection fraction. The Rho-associated coiled-coil containing kinases (ROCKs) are members of the serine/threonine protein kinase family, which mediates the downstream effects of the small GTP-binding protein RhoA. There are 2 isoforms: ROCK1 and ROCK2. They have different functions in different types of cells and tissues. There is growing evidence that ROCKs contribute to the development of cardiovascular diseases, including cardiac fibrosis, hypertrophy, and subsequent heart failure. Recent experimental studies using ROCK inhibitors, such as fasudil, have shown the benefits of ROCK inhibition in cardiac remodeling. Mice lacking each ROCK isoform also exhibit reduced myocardial fibrosis in a variety of pathological models of cardiac remodeling. Indeed, clinical studies with fasudil have suggested that ROCKs could be potential novel therapeutic targets for cardiovascular diseases. In this review, we summarize the current understanding of the roles of ROCKs in the development of cardiac fibrosis and hypertrophy and discuss their therapeutic potential for deleterious cardiac remodeling. (Circ J 2016; 80: 1491-1498).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27251065      PMCID: PMC5563468          DOI: 10.1253/circj.CJ-16-0433

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  89 in total

1.  Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis.

Authors:  Yong Zhou; Xiangwei Huang; Louise Hecker; Deepali Kurundkar; Ashish Kurundkar; Hui Liu; Tong-Huan Jin; Leena Desai; Karen Bernard; Victor J Thannickal
Journal:  J Clin Invest       Date:  2013-02-22       Impact factor: 14.808

2.  ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.

Authors:  O Nakagawa; K Fujisawa; T Ishizaki; Y Saito; K Nakao; S Narumiya
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

3.  RhoA protects the mouse heart against ischemia/reperfusion injury.

Authors:  Sunny Yang Xiang; Davy Vanhoutte; Dominic P Del Re; Nicole H Purcell; Haiyun Ling; Indroneal Banerjee; Julie Bossuyt; Richard A Lang; Yi Zheng; Scot J Matkovich; Shigeki Miyamoto; Jeffery D Molkentin; Gerald W Dorn; Joan Heller Brown
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

4.  A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats.

Authors:  S Tada; H Iwamoto; M Nakamuta; R Sugimoto; M Enjoji; Y Nakashima; H Nawata
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

5.  Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice.

Authors:  Ping Fu; Fang Liu; Spencer Su; Wansheng Wang; Xiao R Huang; Mark L Entman; Robert J Schwartz; Lei Wei; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

Review 6.  The war against heart failure: the Lancet lecture.

Authors:  Eugene Braunwald
Journal:  Lancet       Date:  2014-11-16       Impact factor: 79.321

7.  Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.

Authors:  Ping-Yen Liu; Yen-Wen Liu; Li-Jen Lin; Jyh-Hong Chen; James K Liao
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

8.  Increased rho-kinase activity in hypertensive patients with left ventricular hypertrophy.

Authors:  Luigi Gabrielli; Jose L Winter; Ivan Godoy; Paul McNab; Ivonne Padilla; Samuel Cordova; Paola Rigotti; Ulises Novoa; Italo Mora; Lorena García; Maria P Ocaranza; Jorge E Jalil
Journal:  Am J Hypertens       Date:  2013-12-21       Impact factor: 2.689

9.  Rho-associated kinase of chicken gizzard smooth muscle.

Authors:  J Feng; M Ito; Y Kureishi; K Ichikawa; M Amano; N Isaka; K Okawa; A Iwamatsu; K Kaibuchi; D J Hartshorne; T Nakano
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

10.  Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Chunguo Jiang; Hui Huang; Jia Liu; Yanxun Wang; Zhiwei Lu; Zuojun Xu
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

View more
  40 in total

1.  Rho kinase signaling and cardiac physiology.

Authors:  Yuan Dai; Weijia Luo; Jiang Chang
Journal:  Curr Opin Physiol       Date:  2017-12-13

2.  Different roles of myocardial ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice.

Authors:  Shinichiro Sunamura; Kimio Satoh; Ryo Kurosawa; Tomohiro Ohtsuki; Nobuhiro Kikuchi; Md Elias-Al-Mamun; Toru Shimizu; Shohei Ikeda; Kota Suzuki; Taijyu Satoh; Junichi Omura; Masamichi Nogi; Kazuhiko Numano; Mohammad Abdul Hai Siddique; Satoshi Miyata; Masahito Miura; Hiroaki Shimokawa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

Review 3.  Pleiotropic Effects of Statins on the Cardiovascular System.

Authors:  Adam Oesterle; Ulrich Laufs; James K Liao
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

4.  Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion.

Authors:  Chengyu Xiang; Yeqian Zhu; Maohua Xu; Dingguo Zhang
Journal:  J Cardiovasc Transl Res       Date:  2022-05-12       Impact factor: 4.132

5.  Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction.

Authors:  Toru Shimizu; Nikhil Narang; Phetcharat Chen; Brian Yu; Maura Knapp; Jyothi Janardanan; John Blair; James K Liao
Journal:  JCI Insight       Date:  2017-07-06

Review 6.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

7.  Reverse Remodeling in Human Heart Failure after Cardiac Resynchronization Therapy Is Associated With Reduced RHO-Kinase Activation.

Authors:  Maria Paz Ocaranza; Jorge E Jalil; Rodrigo Altamirano; Ana de León; Jackeline Moya; Alejandra Lonis; Luigi Gabrielli; Paul Mac Nab; Samuel Córdova; Alejandro Paredes; Ismael Vergara; Alex Bittner; Karime Sabat; Karla Pastorini
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 8.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.

Authors:  Begoña López; Susana Ravassa; María U Moreno; Gorka San José; Javier Beaumont; Arantxa González; Javier Díez
Journal:  Nat Rev Cardiol       Date:  2021-02-10       Impact factor: 32.419

9.  MicroRNA-145-5p inhibits hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes by targeting ROCK1.

Authors:  Chao Cheng; Dong-Ling Xu; Xiao-Bo Liu; Shao-Jie Bi; Juan Zhang
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

Review 10.  Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.

Authors:  Nehal J Patel; Drew M Nassal; Daniel Gratz; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2020-11-23       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.